Effectiveness of hormones in postmenopausal pelvic floor dysfunction-International Urogynecological Association research and development-committee opinion.
Hormonal treatment
Pelvic organ prolapse
Postmenopausal women
Sex steroids
Urinary incontinence
Vulvovaginal symptoms
Journal
International urogynecology journal
ISSN: 1433-3023
Titre abrégé: Int Urogynecol J
Pays: England
ID NLM: 101567041
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
11
05
2019
accepted:
24
07
2019
pubmed:
9
8
2019
medline:
24
6
2021
entrez:
9
8
2019
Statut:
ppublish
Résumé
There is clear evidence of the presence of estradiol receptors (ERs) in the female lower urinary and genital tract. Furthermore, it is a fact that estrogen deficiency after menopause may cause atrophic changes of the urogenital tract as well as various urinary symptoms. Moreover, the effect of hormone replacement therapy (HRT) on urinary incontinence (UI) symptoms as well as pelvic organ prolapse (POP), anal incontinence (AI) and vulvovaginal symptoms (VVS) is still a matter of debate. This committee opinion paper summarizes the best evidence on influence of sex steroids as well as hormonal treatment (local and systemic) in postmenopausal women with pelvic floor disorders. A working subcommittee from the International Urogynecology Association (IUGA) Research and Development Committee was formed. A thorough literature search was conducted and an opinion statement expressed. The literature regarding hormones and pelvic floor disorders was reviewed independently and summarized by the individual members of the sub-committee. The majority of studies reported that vaginal estrogen treatment when compared with placebo has more beneficial effects on symptoms and signs of vaginal atrophy including sensation of burning, dyspareunia and UI symptoms. Definitive evidence on local estrogen application and prolapse treatment or prevention is lacking. A statistically significant increase in risk of worsening of UI as well as development of de novo incontinence was observed with estrogen-only or combination systemic HRT. In summary, local estrogen seems to be safe and effective in the treatment of VVS and can also improve urinary symptoms in postmenopausal patients with UI, but most of these recommendations correspond to evidence level 2C. The evidence in POP is still scarce but not in favor of benefit. Finally, the duration of local estrogen treatment (LET), optimal dosage, long-term effects and cost-effectiveness compared with current practice are still unknown.
Identifiants
pubmed: 31392363
doi: 10.1007/s00192-019-04070-0
pii: 10.1007/s00192-019-04070-0
pmc: PMC7363722
doi:
Substances chimiques
Estrogens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1577-1582Références
Rogers RG, Villareal A, Kammerer-Doak D, Qualls C. Sexual function in women with and without urinary incontinence and/or pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct. 2011;12:361–5.
doi: 10.1007/s001920170012
Rahn DD, Good MM, Roshanravan SM, Shi H, Schaffer JI, Singh RJ, et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. J Clin Endocrinol Metab. 2014;99(10):3728–36.
pubmed: 24947034
pmcid: 4184065
doi: 10.1210/jc.2014-1216
Swift S, Woodman P, O’Boyle A, et al. Pelvic organ support study (POSST): the distribution, clinical definition and epidemiologic condition of pelvic organ support defects. Am J Obstet Gynecol. 2015;192:795–806.
doi: 10.1016/j.ajog.2004.10.602
Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.
pubmed: 12117397
doi: 10.1001/jama.288.3.321
Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (HERS) research group. JAMA. 1998;280(7):605–13.
pubmed: 9718051
doi: 10.1001/jama.280.7.605
Gandhi J, Chen A, Daqur G, Suh Y, Smith N, Cali B, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215(6):704–11.
pubmed: 27472999
doi: 10.1016/j.ajog.2016.07.045
Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology. 2003;62(4 Suppl 1):45–51.
pubmed: 14550837
doi: 10.1016/S0090-4295(03)00676-9
Söderberg MW, Johansson B, Masironi B, Byström B, Falconer C, Sahlin L, et al. Pelvic floor sex steroid hormone receptors, distribution and expression in pre- and postmenopausal stress urinary incontinent women. Acta Obstet Gynecol Scand. 2007;86(11):1377–84.
pubmed: 17963065
doi: 10.1080/00016340701625446
Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20:130–40.
pubmed: 24456314
Weber MA, Kleijn MH, Langendam M, Heineman MJ, Roovers JP. Local oestrogen for pelvic floor disorders. A systematic review. PLoS One. 2015;10(9):e 0136265.
doi: 10.1371/journal.pone.0136265
Cardozo L, Gunnar L, McClish D, Versi E, et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004;83:892–7.
pubmed: 15453881
doi: 10.1111/j.0001-6349.2004.00581.x
Hanna-Mitchell AT, Robinson D, Cardozo L, Everaert K, Petkov GV. Do we need to know more about the effects of hormones on lower urinary tract dysfunction? ICI-RS 2014. Neurourol Urodyn. 2016;35(2):299–303.
pubmed: 26872571
pmcid: 6103166
doi: 10.1002/nau.22809
Eriksen PS, Rasmussen H. Low dose 17b-oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol. 1992;44:137–44.
pubmed: 1587379
doi: 10.1016/0028-2243(92)90059-8
Nelken RS, Ozel BZ, Leegant AR, Felix JC, Mishell DR. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause. 2011;18(9):962–6.
pubmed: 21532512
doi: 10.1097/gme.0b013e3182104977
Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurorurol Urodyn. 2009;28(1):47–51.
doi: 10.1002/nau.20583
Rahn DD, Ward RM, Sanses TV, Carberry C, Mamik MM, Meriwether KV, et al. Vaginal estrogen in postmenopausal women with pelvic floor disorers: systematic review and practice guidelines. Int Urogynecol J. 2015;26(1):3–13.
pubmed: 25392183
doi: 10.1007/s00192-014-2554-z
Ellington DR, Szychowski JM, Malek JM, Gerten KA, Burgio KL, Richter HE. Combined Tolterodine and vaginal estradiol cream for overactive bladder symptoms after randomized single-therapy treatment. Female Pelvic Med Reconstr Surg. 2016;22(4):254–60.
pubmed: 26945271
pmcid: 4919279
doi: 10.1097/SPV.0000000000000256
Schiavi MC, D’Oria O, Aleksa N, Vena F, Prata G, Di Tucci C, et al. Usefulness of ospemifene in the treatment of urgency in menopausal patients affected by mixed urinary incontinence underwent mid-urethral slings surgery. Gynecol Endocrinol. 2019;35(2):155–9.
pubmed: 30324854
doi: 10.1080/09513590.2018.1500534
Schiavi MC, Sciuga V, Giannini A, Vena F, D’oria O, Prata G, et al. Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality? Gynecol Endocrinol. 2018;34(8):666–9.
pubmed: 29463148
doi: 10.1080/09513590.2018.1441398
Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the hormones and urogenital therapy committee. Obstet Gynecol. 1998;92(4):722–7.
pubmed: 9764689
doi: 10.1016/S0029-7844(98)00175-6
Mitchell CM, Reed S, Diem S, Larson JC, Newton KM, Ensrud KE, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms a randomized clinical trial. JAMA Intern Med. 2018. https://doi.org/10.1001/jamainternmed.2018.0116 .
Smith L, Brown J, Wyman JF, Berry A, Newman DK, Stapleton AE. Treatment and prevention of recurrent lower urinary tract infections in women: a rapid review with practice recommendations. J Urol. 2018;200(6):1174–91.
pubmed: 29940246
doi: 10.1016/j.juro.2018.04.088
Alperin M, Moalli PA. Remodeling of vaginal connective tissue in patients with prolapse. Curr Opin Obstet Gynecol. 2006;18:544–50.
pubmed: 16932050
doi: 10.1097/01.gco.0000242958.25244.ff
Alperin M, Burnett L, Lukacz E, Brubaker L. The mysteries of menopause and urogynecologic health: clinical and scientific gaps. Menopause. 2019;26(1):103–11.
pubmed: 30300297
pmcid: 6376984
doi: 10.1097/GME.0000000000001209
Bulchandani S, Toozs-Hobson P, Verghese T, Latthe P. Does vaginal estrogen treatment with support pessaries in vaginal prolapse reduce complications? Post Reprod Health. 2015;21(4):141–5.
pubmed: 26537626
doi: 10.1177/2053369115614704
Dessie SG, Armstrong K, Modest AM, Hacker MR, Hota LS. Effect of vaginal estrogen on pessary use. Int Urogynecol J Pelvic Floor Dysfunct. 2016;27(9):1423–9.
doi: 10.1007/s00192-016-3000-1
Karp DR, Jean-Michel M, Johnston Y, Suciu G, Aguilar VC, Davila GW. A randomized trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Med Reconstr Surg. 2012;18(4):211–5.
pubmed: 22777369
doi: 10.1097/SPV.0b013e31825e6401
Vaccaro CM, Fellner AN, Crisp CC, Estanol MV, Kleeman SD, et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse. A randomized controlled trial. Female Pelvic Med Reconstr Surg. 2013;19(1):34–9.
pubmed: 23321657
doi: 10.1097/SPV.0b013e318278cc40
Pinedo G, Garcia E, Zarate AJ, et al. Are topical oestrogens useful in fecal incontinence? Double blind randomized trial. Color Dis. 2009;11:390–3.
doi: 10.1111/j.1463-1318.2008.01624.x
Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Estrogen therapy for urinary incontinence in post-menopausal women. Chochrane Database Syst Rev. 2012;10:CD 001405.
Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the hormones and urogenital therapy committee. Obstet Gynecol. 1994;83:12–8.
pubmed: 8272292
Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293:935–48.
pubmed: 15728164
doi: 10.1001/jama.293.8.935
Staller K, Townsend MK, Khalili H, et al. Menopausal hormone therapy is associated with increased risk of fecal incontinence in women after menopause. Gastroenterology. 2017;152(8):1915–1921.e1.
pubmed: 28209529
pmcid: 5447480
doi: 10.1053/j.gastro.2017.02.005
Ismail SI, Bain C, Hagen S. Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women. Cochrane Database Syst Rev. 2010;9:CD007063. https://doi.org/10.1002/14651858.CD007063 .
doi: 10.1002/14651858.CD007063